

23 February 2026

## CannEpil® – Largest Commercial Shipment Arrives in Ireland

### Highlights:

- **Largest ever commercial shipment of CannEpil® arrives in Ireland, 1,000 units delivered**
- **CannEpil® is fully covered for 100% rebate under the Irish National Health Insurance scheme**
- **Shipment carries an approximate reimbursed retail value of ~AUD 783,000**
- **CannEpil® is developed and clinically researched for the management of seizures associated with Refractory Epilepsy**

Argent BioPharma Ltd (ASX: RGT) (Argent or the Company) is pleased to announce that **1,000 units** of CannEpil® have arrived in Ireland, representing the largest single commercial shipment in the Company's history. The shipment will be distributed by the Company's Irish commercial partner, Georgelle Pharma, with delivery completed in collaboration with its European wholesaler and logistics partner, Versa Pharmaceuticals d.o.o. The delivery of the shipment of 1,000 units of CannEpil® represents a reimbursed retail value of approximately A\$ 783,000.

This delivery follows the production of 1,000 units of CannEpil®, manufactured for the first time via the Company's OEM partner under EU-GMP standards, demonstrating the Company's capability to execute scaled commercial supply under regulated pharmaceutical manufacturing pathways.

### CannEpil® – Product Overview

CannEpil® is Argent BioPharma's Investigational Medicinal Product (IMP) a pharmaceutical-grade, standardised cannabinoid formulation developed for neurological indications. The product is developed and clinically researched for the management of seizures associated with Refractory Epilepsy, a condition in which seizures persist despite treatment with conventional anti-epileptic medications.

Refractory Epilepsy represents a significant unmet medical need globally, with approximately 30% of epilepsy patients failing to achieve adequate seizure control using standard therapies. Patients in this category often experience ongoing seizure burden, reduced quality of life, and increased healthcare utilisation.

CannEpil® is manufactured under EU-GMP standards and incorporates defined cannabinoid ratios with pharmaceutical-grade quality control to ensure batch consistency, safety, and dosing precision. The product has undergone clinical evaluation and is supplied under regulated medical frameworks in multiple jurisdictions.

In Ireland, CannEpil® is supplied through regulated prescribing pathways and is fully reimbursed under the Irish National Health Insurance system, providing eligible patients with access under physician supervision.

### Commercial Milestone

The full shipment has successfully arrived with the Irish wholesaler, representing the largest single delivery of CannEpil® in the Company's history. CannEpil® is fully reimbursed under Ireland's national health reimbursement framework, enabling eligible patients to access treatment through the public healthcare system under physician supervision. This milestone reflects continued commercial traction in a regulated



European market and demonstrates the Company's ability to execute scaled production under its EU-GMP manufacturing pathway.

CannEpi<sup>®</sup> carries a National Health Insurance retail reimbursement price of €467 per unit, equating to an approximate total retail value of ~AUD 783,000 for the shipment. At this stage, revenues attributable to Argent BioPharma cannot be precisely quantified and will depend on, among other things, the number of units ultimately dispensed and reimbursed, and the pricing/settlement mechanics and deductions across the distribution chain within the Irish healthcare framework. The successful delivery further strengthens Argent BioPharma's European distribution infrastructure, expands reimbursed patient access within a regulated healthcare system, and supports the continued commercialisation of CannEpi<sup>®</sup> as a core component of the Company's neurological portfolio.

**Argent BioPharma Managing Director and CEO, Roby Zomer, Commented:**

*"This shipment represents a meaningful commercial inflection point for Argent BioPharma, demonstrating our ability to execute scaled EU-GMP manufacturing and deliver reimbursed product into a regulated national healthcare system. Beyond its immediate commercial impact, the milestone strengthens CannEpi<sup>®</sup>'s position within our neurological portfolio and validates our European supply and distribution infrastructure. Importantly, this delivery aligns operational execution, market access, and clinical positioning as we advance the next phase of the Company's growth strategy."*

—Ends—

Authorised for release by the board of directors, for further information please contact:

**Argent BioPharma**  
Roby Zomer  
CEO & Managing Director  
+61 8 6555 2950  
[info@argentbiopharma.com](mailto:info@argentbiopharma.com)

**Argent BioPharma**  
Rowan Harland  
Company Secretary  
+61 8 6555 2950  
[info@argentbiopharma.com](mailto:info@argentbiopharma.com)

**About Argent BioPharma**

**Argent BioPharma Ltd. (ASX: RGT)** is a revenue-generating, clinical-stage biopharmaceutical company focused on the development and commercialisation of nano-engineered therapeutics targeting neurological and immune-mediated disorders. Its lead assets, CannEpi<sup>®</sup> and CimetrA<sup>®</sup>, are being advanced for drug-resistant epilepsy and inflammatory conditions, respectively. The Company leverages proprietary nano-delivery technologies designed to optimise bioavailability and tissue penetration, including across the blood-brain barrier and pulmonary interfaces. With vertically integrated EU-GMP manufacturing, a unified Neuro-Immune Modulatory platform, and ongoing clinical development programs, Argent BioPharma is advancing a focused pipeline targeting central nervous system and systemic inflammatory conditions with significant unmet medical need

Follow us through our social media channels:

LinkedIn: Argent BioPharma  
Twitter: @ArgentBioPharma  
Facebook: Argent BioPharma

